v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net Revenue $ 27,798,534 $ 23,434,096
Cost of goods sold 1,923,589 1,834,967
Gross profit 25,874,945 21,599,129
Operating expenses    
Selling, general and administrative 21,881,520 19,129,208
Research and development 759,592 950,359
Depreciation and amortization [1],[2] 587,252 694,032
Total operating expenses 23,228,364 20,773,599
Operating income 2,646,581 825,530
Other income (expense)    
Interest expense (1,799,345) (1,317,092)
Share of losses from equity method investments (462,507) (143,608)
Interest income 12,958 3,672
Gain on disposal of property and equipment 10,932
Total other income (expense) [3] (2,248,894) (1,446,096)
Net income (loss) from continuing operations 397,687 (620,566)
Net income (loss) from discontinued operations (Note 3) 60,916 (2,906,817)
Net income (loss) 458,603 (3,527,383)
Less: Net loss attributable to noncontrolling interest from continuing operations (354) (206)
Net income (loss) attributable to Sanara MedTech shareholders $ 458,957 $ (3,527,177)
Net income (loss) per share, basic:    
Continuing operations $ 0.04 $ (0.07)
Discontinued operations 0.01 (0.34)
Net income (loss) per share of common stock, basic 0.05 (0.41)
Net income (loss) per share, diluted:    
Continuing operations 0.04 (0.07)
Discontinued operations 0.01 (0.34)
Net income (loss) per share of common stock, diluted $ 0.05 $ (0.41)
Weighted average number of common shares outstanding, basic 8,706,678 8,570,104
Weighted average number of common shares outstanding, diluted 8,985,866 8,570,104
[1] Depreciation expense of $5,461 was reclassified as continuing operations in the three months ended March 31, 2025 and is therefore no longer reflected in discontinued operations.
[2] Depreciation expense of $5,461 was reclassified as continuing operations in the three months ended March 31, 2025 and is therefore no longer reflected in discontinued operations.
[3] For the three months ended March 31, 2026, other expense included interest expense and share of losses from equity method investments, offset by interest income. For the three months ended March 31, 2025, other expense included interest expense and share of losses from equity method investments, offset by interest income and gain on disposal of property and equipment.